Sotio, a Czech Republic-based biotechnology company developing a next generation Active Cellular Immunotherapy, has selected Chiltern International to be the CRO that carries out the European part of its phase III global clinical trial titled VIABLE, which will include 1,170 prostate cancer patients from Europe and the U.S.
Chiltern will be responsible for providing full-service management of the VIABLE phase III clinical trial in Europe. It will be the contracting party for 126 treatment centers in 17 European countries where a total of 750 patients are expected to participate in the trial. Chiltern will also be responsible for processing the data obtained during this clinical evaluation.
Dr. Jim Esinhart, CEO of Chiltern, said, "I am very pleased that we have been selected to manage this high profile trial. I believe it underscores the strengths and expertise of our global Oncology Therapeutic Area Team. We look forward to working in close partnership with Sotio to deliver a quality outcome."